153.29
price up icon1.73%   2.61
after-market After Hours: 153.29
loading
Neurocrine Biosciences Inc stock is traded at $153.29, with a volume of 834.63K. It is up +1.73% in the last 24 hours and up +11.84% over the past month. Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$150.68
Open:
$152
24h Volume:
834.63K
Relative Volume:
0.85
Market Cap:
$15.52B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
41.10
EPS:
3.73
Net Cash Flow:
$440.10M
1W Performance:
+3.87%
1M Performance:
+11.84%
6M Performance:
+8.58%
1Y Performance:
+7.91%
1-Day Range:
Value
$151.14
$154.61
1-Week Range:
Value
$145.97
$154.61
52-Week Range:
Value
$110.95
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,700
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
153.29 15.52B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
172.71 77.92B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.70 43.43B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.57 43.27B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.84 20.21B 16.77B -959.00M 1.37B -0.85

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
08:17 AM

Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 146,105 Shares of Stock - MarketBeat

08:17 AM
pulisher
04:01 AM

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results - Victoria Advocate

04:01 AM
pulisher
02:36 AM

Neurocrine Biosciences director sells shares worth $21.8 million - MSN

02:36 AM
pulisher
Jan 29, 2025

Neurocrine Biosciences director sells shares worth $21.8 million By Investing.com - Investing.com Australia

Jan 29, 2025
pulisher
Jan 29, 2025

Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - Investing.com

Jan 29, 2025
pulisher
Jan 29, 2025

Prentiss Smith & Co. Inc. Invests $650,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Jan 29, 2025
pulisher
Jan 29, 2025

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance

Jan 29, 2025
pulisher
Jan 29, 2025

Stifel maintains Neurocrine Bio stock target, positive on Takeda deal - MSN

Jan 29, 2025
pulisher
Jan 28, 2025

Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder - Marketscreener.com

Jan 28, 2025
pulisher
Jan 28, 2025

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights - Benzinga

Jan 28, 2025
pulisher
Jan 28, 2025

Neurocrine revamps osavampator deal with Takeda - The Pharma Letter

Jan 28, 2025
pulisher
Jan 28, 2025

Stifel maintains Neurocrine Bio stock target, positive on Takeda deal By Investing.com - Investing.com Nigeria

Jan 28, 2025
pulisher
Jan 28, 2025

Game-Changing Depression Drug Enters Final Testing PhaseCould Help Millions Where Others Failed - StockTitan

Jan 28, 2025
pulisher
Jan 27, 2025

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences - MarketWatch

Jan 27, 2025
pulisher
Jan 27, 2025

Neurocrine Amends Collaboration with Takeda on Osavampator -January 27, 2025 at 05:30 pm EST - Marketscreener.com

Jan 27, 2025
pulisher
Jan 27, 2025

Neurocrine Biosciences Announces to Develop and Commercialize Osavampator -January 27, 2025 at 04:05 pm EST - Marketscreener.com

Jan 27, 2025
pulisher
Jan 27, 2025

Where are the Opportunities in (NBIX) - Stock Traders Daily

Jan 27, 2025
pulisher
Jan 27, 2025

Wedbush Forecasts Weaker Earnings for Neurocrine Biosciences - MarketBeat

Jan 27, 2025
pulisher
Jan 25, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Increased by Harel Insurance Investments & Financial Services Ltd. - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Daymark Wealth Partners LLC Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - MarketBeat

Jan 25, 2025
pulisher
Jan 24, 2025

Andrew Ratz, Ph.D., Appointed Senior Vice President of Drug Development at Neurocrine Biosciences - citybiz

Jan 24, 2025
pulisher
Jan 24, 2025

Neurocrine appoints Andrew Ratz as senior VP - The Pharma Letter

Jan 24, 2025
pulisher
Jan 24, 2025

Neurocrine Biosciences Appoints SVP of Drug Development, Delivery and Device - Contract Pharma

Jan 24, 2025
pulisher
Jan 24, 2025

2,735 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by HB Wealth Management LLC - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device - Financial Times

Jan 23, 2025
pulisher
Jan 23, 2025

Dyskinesia Pipeline 2024: Latest FDA Approvals, Clinical - openPR

Jan 23, 2025
pulisher
Jan 23, 2025

Whalen Wealth Management Inc. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Neurocrine backs CAH-focused supplement in JCEM - MSN

Jan 23, 2025
pulisher
Jan 22, 2025

Neurocrine backs CAH-focused supplement in JCEM By Investing.com - Investing.com Australia

Jan 22, 2025
pulisher
Jan 22, 2025

Brokers Set Expectations for NBIX FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Reduces Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Jan 22, 2025
pulisher
Jan 21, 2025

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism - PR Newswire

Jan 21, 2025
pulisher
Jan 21, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Neurocrine's CRENESSITY Breakthrough Featured in Major Endocrinology Journal Special Issue - StockTitan

Jan 21, 2025
pulisher
Jan 19, 2025

Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Neurocrine Bio stock retains outperform rating on robust pipeline - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Avanza Fonder AB Invests $1.80 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Kyle Gano Sells 65,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-15-2023 08 - Marketscreener.com

Jan 17, 2025
pulisher
Jan 17, 2025

Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock By Investing.com - Investing.com UK

Jan 17, 2025
pulisher
Jan 16, 2025

How To Trade (NBIX) - Stock Traders Daily

Jan 16, 2025
pulisher
Jan 16, 2025

Endometriosis Pipeline 2024: Detailed Clinical Trials - openPR

Jan 16, 2025
pulisher
Jan 16, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Burney Co. - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law

Jan 15, 2025
pulisher
Jan 15, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $164.81 Consensus PT from Brokerages - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

40 Under 40: Ashley Allan, Neurocrine Biosciences - MM+M Online

Jan 14, 2025
pulisher
Jan 13, 2025

Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - GlobeNewswire

Jan 13, 2025
pulisher
Jan 13, 2025

Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio - The Manila Times

Jan 13, 2025
pulisher
Jan 09, 2025

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.

Jan 09, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences explores new CAH treatments By Investing.com - Investing.com Canada

Jan 08, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$11.42
price up icon 0.79%
$127.00
price down icon 0.02%
$17.84
price down icon 3.78%
$92.79
price up icon 0.28%
$12.47
price up icon 1.46%
Cap:     |  Volume (24h):